The U.S. Food and Drug Administration (FDA) is conducting an investigation to determine if Fresenius Medical Care, the world's largest dialysis... read more
GranuFloHelp.com is sponsored by a team of attorneys who are investigating possible lawsuits on behalf of dialysis patients who suffered cardiac arrest and other serious heart complications shortly after dialysis.
If you or someone you love suffered a heart complication or if your loved one died from sudden cardiac arrest within 48 hours of dialysis, you may be eligible to seek financial compensation by filing a GranuFlo® lawsuit. To learn more, schedule a free and private consultation with our attorneys today.
History Behind GranuFlo® Lawsuits
Patients who need dialysis usually suffer from acidosis, a buildup of acid in the blood. Acid concentrates such as GranuFlo® are used in conjunction with bicarbonate concentrates during hemodialysis to neutralize the acid buildup. Acid concentrates such as GranuFlo® contain acetate, an ingredient that body turns into bicarbonate.
In 2010 Fresenius Medical Care, the maker of GranuFlo®, discovered that physicians weren't taking into account the fact that GranuFlo® and NaturaLyte®, another acid concentrate produced by Fresenius, contain higher levels of acetate than other concentrates. Too much bicarbonate in the blood can cause metabolic alkalosis, a dangerous condition associated with:
- Low blood pressure
- Cardiac arrhythmia
- Cardiopulmonary arrest
When Fresenius discovered the risk of cardiac death it issued an internal memo to the practicing physicians at its own centers. The memo stated that 941 patients suffered cardiac arrest in Fresenius centers in 2010 and provided the physicians with instructions on how to properly prescribe GranuFlo®.
In what seems to be an effort to protect its market share, Fresenius failed to warn physicians at non-Fresenius clinics about the risk. It wasn't until months later when the FDA questioned the company about the connection between cardiac arrest and GranuFlo® that it issued another memo. The FDA reportedly received a copy of the internal memo from an anonymous source.
The FDA issued a class I recall of GranuFlo® and NaturaLyte® on March 29, 2012 and is reportedly investigating whether Fresenius violated federal regulations by withholding information from non-Fresenius centers. During the months that the company withheld the information, thousands of patients were put at risk.
Talk to a GranuFlo® Attorney
If you or someone you love has suffered a heart complication or if someone you love suffered cardiac death after dialysis, you can seek help by contacting us today. Our attorneys have taken a special interest in this legal matter and are helping affected patients and their families.